A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study
- Author:
Ting DENG
1
;
Kaijiang LIU
;
Liang CHEN
;
Xiaojun CHEN
;
Hua Wen LI
;
Hongyan GUO
;
Huijiao ZHANG
;
Libing XIANG
;
Xin FENG
;
Xiaoyu WANG
;
Hextan YS NGAN
;
Jianguo ZHAO
;
Dongling ZOU
;
Qing LIU
;
Jihong LIU
Author Information
- Publication Type:Clinical Trial Protocol
- From:Journal of Gynecologic Oncology 2023;34(3):e52-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients with clinically normal lymph nodes and was associated with a higher incidence of operative complications. However, there is no consensus on whether lymphadenectomy has survival benefit or not in early epithelial ovarian cancer (EOC).
Methods:We designed the LOVE study, a multicenter, randomized controlled, phase III trial to compare the efficacy and safety of comprehensive staging surgery with or without lymphadenectomy in stages IA-IIB EOC and fallopian tube carcinomas (FTC). The hypothesis is that the oncological outcomes provided by comprehensive staging surgery without lymphadenectomy are non-inferior to those of conventional completion staging surgery in early-stage EOC and FTC patients who have indications for post-operative adjuvant chemotherapy. Patients assigned to experimental group will undergo comprehensive staging surgery, but lymphadenectomy. Patients assigned to comparative group will undergo completion staging surgery including systematic pelvic and para-aortic lymphadenectomy. All subjects will receive 3–6 cycles of standard adjuvant chemotherapy. Major inclusion criteria are pathologic confirmed stage IA-IIB EOC or FTC, and patients have indications for adjuvant chemotherapy either confirmed by intraoperative fast frozen section or previous pathology after an incomplete staging surgery. Major exclusion criteria are non-epithelial tumors and low-grade serous carcinoma. Patients with severe rectum involvement which lead to partial rectum resection will be excluded. The sample size is 656 subjects. Primary endpoint is disease-free survival.
